Interleukin-6 in oral diseases: A review

Oral Diseases

Volumn 18, Issue 3, 2012, Pages 236-243

  Nibali, L ^a   Fedele, S ^a   D'Aiuto, F ^a   Donos, N ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Interleukin 6; Lichen planus; Oral cancer; Oral diseases; Periodontitis; Sj gren's syndrome

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

APHTHOUS STOMATITIS; ARTICLE; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; GENETIC REGULATION; GINGIVITIS; HUMAN; KERATINOCYTE; LANGERHANS CELL; LICHEN PLANUS; MOUTH CANCER; MOUTH DISEASE; MOUTH LICHEN PLANUS; NONHUMAN; PERIODONTAL DISEASE; PERIODONTITIS; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULPITIS; SJOEGREN SYNDROME;

DENTAL PULP DISEASES; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LICHEN PLANUS, ORAL; MOUTH DISEASES; MOUTH NEOPLASMS; PERIODONTAL DISEASES; SJOGREN'S SYNDROME;

EID: 84857796273     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2011.01867.x     Document Type: Article

References (119)

1. Alevizos I, Mahadevappa M, Zhang X et al (2001). Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis. Oncogene 20: 6196-6204.
2. Balto K, Sasaki H, Stashenko P (2001). Interleukin-6 deficiency increases inflammatory bone destruction. Infect Immun 69: 744-750.
3. Barkhordar RA, Hayashi C, Hussain MZ (1999). Detection of interleukin-6 in human dental pulp and periapical lesions. Endod Dent Traumatol 15: 26-27.
4. Barton BE (2005). Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes. Expert Opin Ther Targets 9: 737-752.
5. Bazrafshani MR, Hajeer AH, Ollier WE, Thornhill LH (2002). IL-1β and IL-6 gene polymorphisms encode significant risk for the development of recurrent aphthous stomatitis (RAS). Genes Immun 3: 302-305.
6. Becerik S, Ozcaka O, Nalbantsoy A et al (2010). Effects of menstrual cycle on periodontal health and gingival crevicular fluid markers. J Periodontol 81: 673-681.
7. Belibasakis GN, Johansson A, Wang Y et al (2005). Cytokine responses of human gingival fibroblasts to Actinobacillus actinomycetemcomitans cytolethal distending toxin. Cytokine 30: 56-63.
8. Bennermo M, Held C, Stemme S et al (2004). Genetic predisposition of the interleukin-6 response to inflammation: implications for a variety of major diseases? Clin Chem 50: 2136-2140.
9. Bermejo-Fenoll A, Sanchez-Siles M, López-Jornet P, Camacho-Alonso F, Salazar-Sanchez N (2009). Premalignant nature of oral lichen planus. A retrospective study of 550 oral lichen planus patients from south-eastern Spain. Oral Oncol 45: 54-56.
10. Bigbee WL, Grandis JR, Siegfried JM (2007). Multiple cytokine and growth factor serum biomarkers predict therapeutic response and survival in advanced-stage head and neck cancer patients. Clin Cancer Res 13: 3107-3108.
11. Carrozzo M, de Capei MU, Dametto E et al (2004). Tumor necrosis factor-alpha and interferon-gamma polymorphisms contribute to susceptibility to oral lichen planus. J Invest Dermatol 122: 87-94.
12. Chen Z, Malhotra PS, Thomas GR et al (1999). Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5: 1369-1379.
13. Costa PP, Trevisan GL, Macedo GO et al (2010). Salivary interleukin-6, matrix metalloproteinase-8, and osteoprotegerin in patients with periodontitis and diabetes. J Periodontol 81: 384-391.
14. D'Aiuto F, Parkar M, Andreou G et al (2004a). Periodontitis and systemic inflammation: control of the local infection is associated with a reduction in serum inflammatory markers. J Dent Res 83: 156-160.
15. D'Aiuto F, Parkar M, Brett PM, Ready D, Tonetti MS (2004b). Gene polymorphisms in pro-inflammatory cytokines are associated with systemic inflammation in patients with severe periodontal infections. Cytokine 28: 29-34.
16. D'Aiuto F, Nibali L, Parkar M, Suvan J, Tonetti MS (2005). Short-term effects of intensive periodontal therapy on serum inflammatory markers and cholesterol. J Dent Res 84: 269-273.
17. De Sa AR, Pimenta FJGS, Dutra WO, Gomez RS (2003). Immunolocalization of interleukin 4, interleukin 6, and lymphotoxin alpha in dental granulomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 96: 356-360.
18. De Sa AR, Moreira PR, Xavier GM et al (2007). Association of CD14, IL1B, IL6, IL10 and TNFA functional gene polymorphisms with symptomatic dental abscesses. Int Endod J 40: 563-572.
19. d'Elia HF, Bjurman C, Rehnberg E, Kvist G, Konttinen YT (2009). Interleukin 6 and its soluble receptor in a central role at the neuroimmunoendocrine interface in Sjogren syndrome: an explanatory interventional study. Ann Rheum Dis 68: 285-286.
20. Fauchais AL, Martel C, Gondran G et al (2010). Immunological profile in primary Sjögren syndrome: clinical significance, prognosis and long-term evolution to other auto-immune disease. Autoimmun Rev 9: 595-599.
21. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2008). GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer, Lyon, France. Available at: [accessed on 20 September 2010].
22. Fife MS, Ogilvie EM, Kelberman D et al (2005). Novel IL-6 haplotypes and disease association. Genes Immun 6: 367-370.
23. Fishman D, Faulds G, Jeffery R et al (1998). The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102: 1369-1376.
24. Franch-Chillida F, Nibali L, Madden I, Donos N, Brett P (2010). Association between interleukin-6 polymorphisms and periodontitis in Indian non-smokers. J Clin Periodontol 37: 137-144.
25. Fujihashi K, Beagley KW, Kono Y et al (1993). Gingival mononuclear-cells from chronic inflammatory periodontal tissues produce interleukin (IL)-5 and IL-6 but not IL-2 and IL-4. Am J Pathol 142: 1239-1250.
26. Galicia JC, Tai H, Komatsu Y, Shimada Y, Akazawa K, Yoshie H (2004). Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. Genes Immun 5: 513-516.
27. Galicia JC, Tai H, Komatsu Y, Shimada Y, Ikezawa I, Yoshie H (2006). Interleukin-6 receptor gene polymorphisms and periodontitis in a non-smoking Japanese population. J Clin Periodontol 33: 704-709.
28. Gasche JA, Hoffmann J, Boland CR, Goel A (2011). Interleukin-6 promotes tumorigenesis by altering DNA methylation in oral cancer cells. Int J Cancer 129: 1053-1063.
29. Geivelis M, Turner DW, Pederson ED, Lamberts BL (1993). Measurements of interleukin-6 in gingival crevicular fluid from adults with destructive periodontal-disease. J Periodontol 64: 980-983.
30. Gonzalez-Moles MA, Scully C, Gil-Montoya JA (2008). Oral lichen planus: controversies surrounding malignant transformation. Oral Dis 4: 229-243.
31. Graves DT, Cochran D (2003). The contribution of interleukin-1 and tumor necrosis factor to periodontal tissue destruction. J Periodontol 74: 391-401.
32. Grossman RM, Krueger J, Yourish D et al (1989). Interleukin-6 is expressed in high-levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 86: 6367-6371.
33. Gu GM, Martin MD, Darveau RP, Truelove E, Epstein J (2004). Oral and serum IL-6 levels in oral lichen planus patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98: 673-678.
34. Guimarães AL, Correia-Silva Jde F, Sà AR et al (2007). Investigation of functional gene polymorphisms IL-1b, IL-6, IL-10 and TNF-a in individuals with recurrent aphthous stomatitis. Arch Oral Biol 52: 268-272.
35. Haque MF, Harris M, Meghji S, Barrett AW (1998). Immunolocalization of cytokines and growth factors in oral submucous fibrosis. Cytokine 10: 713-719.
36. Haque MF, Meghji S, Khitab U, Harris M (2000). Oral submucous fibrosis patients have altered levels of cytokine production. J Oral Pathol Med 29: 123-128.
37. Hirano T, Matsuda T, Turner M et al (1988). Excessive production of interleukin-6/B cell stimulatory factor-II in rheumatoid-arthritis. Eur J Immunol 18: 1797-1801.
38. Hirano T, Ishihara K, Hibi M (2000). Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19: 2548-2556.
39. Hohaus S, Massini G, Giachelia M et al (2010). Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol 28: 2538-2543.
40. Holla LI, Musilova K, Vokurka J et al (2008). Association of interleukin-6 (IL-6) haplotypes with plaque-induced gingivitis in children. Acta Odontol Scand 66: 105-112.
41. Hong DS, Angelo LS, Kurzrock R (2007). Interleukin-6 and its receptor in cancer - implications for translational therapeutics. Cancer 110: 1911-1928.
42. Howells GL (1995). Cytokine networks in destructive periodontal disease. Oral Dis 1: 266-270.
43. Huang GTJ, Do M, Wingard M, Park JS, Chugal N (2001). Effect of interleukin-6 deficiency on the formation of periapical lesions after pulp exposure in mice. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92: 83-88.
44. Irwin CR, Myrillas TT (1998). The role of IL-6 in the pathogenesis of periodontal disease. Oral Dis 4: 43-47.
45. Ishii T (1987). Immunohistochemical demonstration of T-cell subsets and accessory cells in oral lichen-planus. J Oral Pathol Med 16: 356-361.
46. Jeng JH, Wang YJ, Chiang BL et al (2003). Roles of keratinocyte inflammation in oral cancer: regulating the prostaglandin E-2, interleukin-6 and TNF-alpha production of oral epithelial cells by areca nut extract and arecoline. Carcinogenesis 24: 1301-1315.
47. Johanssen A, Bjurshammar N, Gustafsson A (2010). The influence of academic stress on gingival inflammation. Int J Dent Hyg 8: 22-27.
48. Jones KG, Brull DJ, Brown LC et al (2001). Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 103: 2260-2265.
49. Jurge S, Kuffer R, Scully C, Porter SR (2006). Mucosal disease series. Number VI. Recurrent aphthous stomatitis. Oral Dis 12: 1-21.
50. Katsifis GE, Rekka S, Motsopoulos RM, Pillemer S, Wahl SM (2009). Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis. Am J Pathol 175: 1167-1177.
51. Kilpi AM, Rich AM, Radden BG, Reade PC (1988). Direct immunofluorescence in the diagnosis of oral mucosal diseases. Int J Oral Maxillofac Surg 17: 6-10.
52. Kishimoto T, Akira S, Narazaki M, Taga T (1995). Interleukin-6 family of cytokines and Gp130. Blood 86: 1243-1254.
53. Kornman K (2008). Mapping the pathogenesis of periodontitis: a new look. J Periodontol 79(8 Suppl): 1560-1568.
54. Lachmann HJ, Quartier P, So A, Hawkins PN (2011). The emerging role of interleukin-1β in autoinflammatory diseases. Arthritis Rheum 63: 314-324.
55. Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K (2005). Current controversies in oral lichen planus: report of an international consensus meeting. Part 2. Clinical management and malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100: 164-178.
56. Mantovani G, Maccio A, Madeddu C et al (2010). Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer. Oncologist 15: 200-211.
57. Marcaccini AM, Meschiari CA, Zuardi LR et al (2009). Gingival crevicular fluid levels of MMP-8, MMP-9, TIMP-2, and MPO decrease after periodontal therapy. J Clin Periodontol 37: 180-190.
58. Matsuki Y, Yamamoto T, Hara K (1992). Detection of inflammatory cytokine messenger-RNA (Messenger RNA)-expressing cells in human inflamed gingiva by combined in situ hybridization and immunohistochemistry. Immunology 76: 42-47.
59. Matsushima K, Ohbayashi E, Takeuchi H, Hosoya S, Abiko Y, Yamazaki M (1998). Stimulation of interleukin-6 production in human dental pulp cells by peptidoglycans from Lactobacillus casei. J Endod 24: 252-255.
60. Matthews JB, Scully CM, Potts AJC (1984). Oral lichen planus - an immunoperoxidase study using monoclonal-antibodies to lymphocyte subsets. Br J Dermatol 111: 587-595.
61. Mignogna MD, Fedele S, Lo Russo L, Lo Muzio L, Bucci E (2004). Immune activation and chronic inflammation as the cause of malignancy in oral lichen planus: is there any evidence. Oral Oncol 40: 120-130.
62. Mignogna MD, Fedele S, Lo Russo L, Mignogna C, de Rosa G, Porter SR (2007). Field cancerization in oral lichen planus. Eur J Surg Oncol 33: 383-389.
63. Mihara M, Kasutani K, Okazaki M et al (2005). Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 5: 1731-1740.
64. Moreau P, Harousseau JL, Wijdenes J, Morineau N, Milpied N, Bataille R (2000). A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br J Haematol 109: 661-664.
65. Nibali L, Ready DR, Parkar M et al (2007). Gene polymorphisms and the prevalence of key periodontal pathogens. J Dent Res 86: 416-420.
66. Nibali L, Tonetti MS, Ready D et al (2008). Interleukin-6 polymorphisms are associated with pathogenic bacteria in subjects with periodontitis. J Periodontol 79: 677-683.
67. Nibali L, D'Aiuto F, Donos N et al (2009a). Association between periodontitis and common variants in the promoter of the interleukin-6 gene. Cytokine 45: 50-54.
68. Nibali L, Donos N, Henderson B (2009b). Periodontal infectogenomics. J Med Microbiol 58: 1269-1274.
69. Nibali L, Donos N, Farrell S et al (2010). Association between IL6 -174 polymorphism and A. actinomycetemcomitans in chronic periodontitis. J Periodontol 81: 1814-1819.
70. Nibali L, Madden I, Franch-Chillida F, Heitz-Mayfield LJA, Brett PM, Donos N (2011). IL6 -174 genotype associated with A. actinomycetemcomitans in Indians. Oral Dis 17: 232-237.
71. Nishimoto N (2010). Interleukin-6 as a therapeutic target in candidate inflammatory diseases. Clin Pharmacol Ther 87: 483-487.
72. Packard RRS, Libby P (2008). Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 54: 24-38.
73. Page RC, Schroeder HE (1976). Pathogenesis of inflammatory periodontal-disease - summary of current work. Lab Invest 34: 235-249.
74. Park MC, Lee SW, Choi ST, Park YB, Lee SK (2007). Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol 36: 101-106.
75. Passoja A, Knuuttila M, Hiltunen L et al (2011). Serum Interleukin-6 may modulate periodontal inflammation in type 1 diabetic subjects. J Clin Periodontol 38: 687-693.
76. Patel AM, Moreland MW (2010). Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Des Devel Ther 1: 236-278.
77. Patil C, Rossa C, Kirkwood KL (2006). Actinobacillus actinomycetemcomitans lipopolysaccharide induces interleukin-6 expression through multiple mitogen-activated protein kinase pathways in periodontal ligament fibroblasts. Oral Microbiol Immunol 21: 392-398.
78. Poikonen K, Lajunen T, Silvennoinen-Kassinen S, Leinonen M, Saikku P (2009). Effects of CD14, TLR2, TLR4, LPB, and IL-6 gene polymorphisms on Chlamydia pneumoniae growth in human macrophages in vitro. Scand J Immunol 70: 34-39.
79. Prso IB, Kocjan W, Simic H et al (2007). Tumor necrosis factor-alpha and interleukin 6 in human periapical lesions. Mediators Inflamm 2007: 38210.
80. Qi L, van Dam RM, Meigs JB, Manson JE, Hunter D, Hu FB (2006). Genetic variation in IL6 gene and type 2 diabetes: tagging-SNP haplotype analysis in large-scale case-control study and meta-analysis. Hum Mol Genet 15: 1914-1920.
81. Rafiq S, Frayling TM, Murray A et al (2007). A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects. Genes Immun 8: 552-559.
82. Raunio T, Nixdorf M, Knuuttila M, Karttunen R, Vainio O, Tervonen T (2007). The extent of periodontal disease and the IL-6 -174 genotype as determinants of serum IL-6 levels. J Clin Periodontol 34: 1025-1030.
83. Raunio T, Knuuttila M, Hiltunen L, Karttunen R, Vainio O, Tervonen T (2009). IL-6 (-174) genotype associated with the extent of periodontal disease in type 1 diabetic subjects. J Clin Periodontol 36: 11-17.
84. Rhodus NL, Cheng B, Myers S, Bowles W, Ho V, Ondrey F (2005). A comparison of the pro-inflammatory, NF-kappaB-dependent cytokines: TNF-alpha, IL-1-alpha, IL-6, and IL-8 in different oral fluids from oral lichen planus patients. Clin Immunol 114: 278-283.
85. Rhodus NL, Cheng B, Bowles W, Myers S, Miller L, Ondrey F (2006). Proinflammatory cytokine levels in saliva before and after treatment of (erosive) oral lichen planus with dexamethasone. Oral Dis 12: 112-116.
86. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997). Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973-979.
87. Roescher N, Tak PP, Illei GG (2009). Cytokines in Sjögren's syndrome. Oral Dis 15: 519-526.
88. Rogers JE, Li F, Coatney DD et al (2007). Actinobacillus actinomycetemcomitans lipopolysaccharide-mediated experimental bone loss model for aggressive periodontitis. J Periodontol 78: 550-558.
89. Roopashree MR, Gondhalekar RV, Shashikanth MC, George J, Thippeswamy SH, Shukla A (2010). Pathogenesis of oral lichen planus - a review. J Oral Pathol Med 39: 729-734.
90. Ruhl S, Hamberger S, Betz R et al (2004). Salivary proteins and cytokines in drug-induced gingival overgrowth. J Dent Res 83: 322-326.
91. Sanderson SC, Kumari M, Brunner EJ et al (2009). Association between IL6 gene variants-174G > C and-572G > C and serum IL-6 levels: interactions with social position in the Whitehall II cohort. Atherosclerosis 204: 459-464.
92. Sato K, Tsuchiya M, Saldanha J et al (1993). Reshaping a human-antibody to inhibit the interleukin 6-dependent tumor-cell growth. Cancer Res 53: 851-856.
93. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA (1990). Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human-blood mononuclear-cells - IL-6 suppresses IL-1 and TNF. Blood 75: 40-47.
94. Sharma M, Bairy I, Pai K et al (2010). Salivary IL-6 levels in oral leukoplakia with dysplasia and its clinical relevance to tobacco habits and periodontitis. Clin Oral Investig [Epub ahead of print].
95. Shimada Y, Komatsu Y, Ikezawa-Suzuki I, Tai H, Sugita N, Yoshie H (2010). The effect of periodontal treatment on serum leptin, interleukin-6, and C-reactive protein. J Periodontol 81: 1118-1123.
96. Shinriki S, Jono H, Ota K et al (2009). Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res 15: 5426-5434.
97. Sie MP, Sayed-Tabatabaei FA, Oei HH et al (2006). Interleukin 6 -174 G/C promoter polymorphism and risk of coronary heart disease: results from the Rotterdam study and a meta-analysis. Arterioscler Thromb Vasc Biol 26: 212-217.
98. Smith AJP, D'Aiuto F, Palmen J et al (2008). Association of serum interleukin-6 concentration with a functional IL6-6331T > C polymorphism. Clin Chem 54: 841-850.
99. Smolen JS, Aletaha D (2011). Interleukin-6 receptor inhibition with tocilizumab and attainment of remission: the role of acute phase reactants. Arthritis Rheum 63: 43-52.
100. Sugerman PB, Savage NW, Seymour GJ (1994). Phenotype and suppressor activity of T-lymphocyte clones extracted from lesions of oral lichen-planus. Br J Dermatol 131: 319-324.
101. Sugerman PB, Satterwhite K, Bigby M (2000). Autocytotoxic T-cell clones in lichen planus. Br J Dermatol 142: 449-456.
102. Sun A, Chia JS, Chang YF, Chiang CP (2002). Serum interleukin-6 level is a useful marker in evaluating therapeutic effects of levamisole and Chinese medicinal herbs on patients with oral lichen planus. J Oral Pathol Med 31: 196-203.
103. Sundelin K, Roberg K, Grenman R, Hakansson L (2005). Effects of cytokines on matrix metalloproteinase expression in oral squamous cell carcinoma in vitro. Acta Otolaryngol 125: 765-773.
104. Takahashi K, Takashiba S, Nagai A et al (1994). Assessment of interleukin-6 in the pathogenesis of periodontal-disease. J Periodontol 65: 147-153.
105. Takano M, Nishihara R, Sugano N et al (2010). The effect of systemic anti-tumor necrosis factor-alpha treatment on Porphyromonas gingivalis infection in type 2 diabetic mice. Arch Oral Biol 55: 379-384.
106. Teles RP, Likhari V, Socransky SS, Haffajee AD (2009). Salivary cytokine levels in subjects with chronic periodontitis and in periodontally healthy individuals: a cross-sectional study. J Periodontal Res 44: 411-417.
107. Tervonen T, Raunio T, Knuuttila M, Karttunen R (2007). Polymorphisms in the CD14 and IL-6 genes associated with periodontal disease. J Clin Periodontol 34: 377-383.
108. Tonetti MS, D'Aiuto F, Nibali L et al (2007). Treatment of periodontitis and endothelial function. N Engl J Med 356: 911-920.
109. Trevilatto PC, Scarel-Caminaga RM, de Brito RB, de Souza AP, Line SRP (2003). Polymorphism at position -174 of IL-6 gene is associated with susceptibility to chronic periodontitis in a Caucasian Brazilian population. J Clin Periodontol 30: 438-442.
110. Trikha M, Corringham R, Klein B, Rossi JF (2003). Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 9: 4653-4665.
111. Vairaktaris E, Iannopoulos A, Vylliotis A et al (2006). Strong association of interleukin-6 -174 G>C promoter polymorphism with increased risk of oral cancer. Int J Biol Markers 21: 246-250.
112. Vairaktaris E, Yapijakis C, Serefoglou Z et al (2008). Gene expression polymorphisms of Interleukins -1beta, -4, -6, -8, -10, and tumor necrosis -alpha, -beta: regression analysis of their effect upon oral squamous cell carcinoma. J Cancer Res Clin Oncol 134: 821-832.
113. Voulgarelis M, Tzioufas AG (2010). Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome. Nat Rev Rheumatol 6: 529-537.
114. Wassel CL, Barret-Connor E, Laughlin GA (2010). Association of circulating C-reactive protein and interleukin-6 with longevity into the 80s and 90s: The Rancho Bernardo Study. J Clin Endocrinol Metab 95: 4748-4755.
115. Wisithphrom K, Windsor LJ (2006). The effects of tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and transforming growth factor-beta 1 on pulp fibroblast mediated collagen degradation. J Endod 32: 853-861.
116. Xavier GM, de Sa AR, Guimaraes AL, da Silva TA, Gomez RS (2007). Investigation of functional gene polymorphisms interleukin-1beta, interleukin-6, interleukin-10 and tumor necrosis factor in individuals with oral lichen planus. J Oral Pathol Med 36: 476-481.
117. Xing Z, Gauldie J, Cox G et al (1998). IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 101: 311-320.
118. Yamaji Y, Kubota T, Sasaguri K et al (1995). Inflammatory cytokine gene-expression in human periodontal-ligament fibroblasts stimulated with bacterial lipopolysaccharides. Infect Immun 63: 3576-3581.
119. Zhang YY, Lin M, Zhang ST et al (2008). NF-kappa B-dependent cytokines in saliva and serum from patients with oral lichen planus: a study in an ethnic Chinese population. Cytokine 41: 144-149.